The organizers of Drug Delivery to the Lungs (DDL) 23, which will take place December 5-7 at the Edinburgh International Conference Centre in Edinburgh, UK, are preparing to accommodate a record number of attendees.
Committee members Mark Hammond and Ben Forbes say that they expect more than 500 OINDP specialists at DDL this year, a mark the meeting just missed in 2011. Over the past few years, they note, participation has increased as the meeting has drawn from a greater geographic range, attracting more attendees from the US, Europe, and developing countries.
DDL has always sought to keep the meeting affordable in order to allow for maximum participation, and the introduction of the Pat Burnell New Investigator Award two years ago has also drawn increasing numbers of young researchers from academia and industry.
Hammond and Forbes also cite the committee’s responsiveness to attendee requests for meeting topics and activities as another reason for the meeting’s popularity. In setting the program each year, the committee considers topics suggested during the previous meeting. At DDL 22, one of the common requests was for more general sessions in addition to specialist areas.
This year’s session topics are:
-
• Drug Discovery and Development, including new approaches to formulation and product development
• Advances in analytical science for respiratory products
• Targeting drug and formulations to the lung
• The inhaled market – where is it going?
The complete program is available on the DDL 23 web site.
For the past two years, DDL has also coordinated with related organizations to provide attendees with the opportunity to participate in an optional pre-meeting workshop. At DDL 21, the European Pharmaceutical Aerosol Group (EPAG) presented the optional workshop, followed by the International Society of Aerosol Medicine (ISAM) at DDL 22.
